Transgenomic
Founded Year
1997Stage
PIPE | IPOTotal Raised
$10MMarket Cap
0.01BStock Price
6.83About Transgenomic
Transgenomic (NASDAQ:TBIO) is a global biotechnology company that advances personalized medicine in oncology and inherited diseases via its products and services for automated high-sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery, and laboratory testing services to the academic and medical research, clinical laboratory, and biopharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Their flagship product is ICE COLD-PCR, which enables use of liquid biopsies for mutation detection.
Loading...
Loading...
Transgenomic Patents
Transgenomic has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/15/2013 | 9/15/2015 | Molecular biology, Polymerase chain reaction, Biotechnology, Molecular biology techniques, Transcription factors | Grant |
Application Date | 3/15/2013 |
|---|---|
Grant Date | 9/15/2015 |
Title | |
Related Topics | Molecular biology, Polymerase chain reaction, Biotechnology, Molecular biology techniques, Transcription factors |
Status | Grant |
Latest Transgenomic News
Jul 14, 2022
News provided by Share this article Share this article The Global Stem Cell Partnering Terms and Agreements 2010-2022 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Partnering agreement structure Average deal terms for stem cells The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals. The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products. Key benefits In-depth understanding of Stem Cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual Stem Cell contracts entered into by leading biopharma companies Identify most active Stem Cell dealmakers since 2010 Insight into terms included in a Stem Cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Stem Cell Partnering Terms and Agreements 2010-2022 is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide. Stem Cell Partnering Terms and Agreements includes: Trends in Stem Cell dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to Stem Cell contract documents Leading Stem Cell deals by value since 2010 Most active Stem Cell dealmakers since 2010. Key Topics Covered:
Transgenomic Frequently Asked Questions (FAQ)
When was Transgenomic founded?
Transgenomic was founded in 1997.
Where is Transgenomic's headquarters?
Transgenomic's headquarters is located at 12325 Emmet Street, Omaha.
What is Transgenomic's latest funding round?
Transgenomic's latest funding round is PIPE.
How much did Transgenomic raise?
Transgenomic raised a total of $10M.
Who are the investors of Transgenomic?
Investors of Transgenomic include LBi International, Iroquois Capital Group, Omicron Capital, Perceptive Advisors, Dorset Management and 6 more.
Who are Transgenomic's competitors?
Competitors of Transgenomic include Gliknik, Immunetrics, BioDelivery Sciences International, Flexion Therapeutics, OpGen and 7 more.
Loading...
Compare Transgenomic to Competitors
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.
Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.
CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.
PrimaDiag is a start-up developing tools to automate biological processes for diagnostics and research
The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution and Lyophilized injection, in areas like anesthialogy and oncology.
Loading...